Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug

Actavis facility in Iceland
Actavis facility in Iceland

Teva ($TEVA) is expecting to close on its buyout of Allergan’s generic drug business, but for now Actavis is still Allergan’s, for better or worse. That means that Allergan ($AGN) is responsible for the recall of more than 50 lots, consisting of nearly 600,000 bottles, of its copy of the ADHD drug Adderall.

According to the most recent FDA Enforcement Report, Actavis is voluntarily recalling 54 lots involving four different dose forms of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets after they failed tests for impurity levels. The recall was initiated in February but was just classified by the FDA last week as a Class II recall. The nationwide includes 38,507 bottles of 5 mg tablets, 114,388 bottles of 10 mg tablets, 257,746 bottles 20 mg tablets and 182,378 bottles of 30 mg tablets.

The manufacturing mess-up comes as Allergan and Teva are awaiting regulatory approval of their $40.5 billion deal. The two had hoped to close the deal at the end of March, but a couple of weeks ago, Teva said the U.S. Federal Trade Commission said it needed more time to evaluate the massive deal. Now the Israeli drugmaker said the closing might be put off until June.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The European Union signed off on the transaction last month, but with caveats. Teva has to sell off some business to even out the playing field, regulators said. The company agreed to sell "a majority" of Allergan's current generics business in the U.K. and Ireland and agreed to jettison molecules in 24 other countries in Europe. In Iceland, where Actavis originated, Teva will discard its own business while hanging onto the Dublin drugmaker's.

- access the recall notices here


Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.